While the relative risk of CHIP carriers is significantly increased, the absolute risk of progression to a—mostly myeloid—hematologic neoplasm is approximately 0.5% to 1% per year [11]. This evidence concerns the gene STUB1 and hematopoietic and lymphoid system neoplasm.